| Stereochemistry | ABSOLUTE |
| Molecular Formula | C11H20O10 |
| Molecular Weight | 312.2705 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 8 / 8 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]1(O[C@H](CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O
InChI
InChIKey=BYZQBCIYLALLPA-NOPGXMAYSA-N
InChI=1S/C11H20O10/c12-1-4(15)7(16)5(2-13)20-11-10(19)9(18)8(17)6(3-14)21-11/h1,4-11,13-19H,2-3H2/t4-,5+,6+,7+,8-,9-,10+,11+/m0/s1
| Molecular Formula | C11H20O10 |
| Molecular Weight | 312.2705 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 8 / 8 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Gaxilose is a synthetic disaccharide that is hydrolyzed in the intestine by the lactase enzyme. Gaxilose is used to diagnose hypolactasia via presence of D-xylose after cleavage by lactase. The Spanish company VenterPharma was issued with marketing authorisation by the Spanish and German regulatory agencies for LacTEST. Diagnosis drug LacTEST® represents a noninvasive method based on oral administration of 4-galactosil-xilose (4-O-β-D galactopiranosil-D-xilose) whose INN is Gaxilose, for hypolactasia diagnosis. This synthetic disaccharide, a substrate of intestinal lactase is hydrolyzed and the result is 2 physiological products: galactose and xylose. Galactose is converted into glucose in the liver and xylose is absorbed from a passive way and partially metabolized endogenously (50%). The rest appears in blood and it is excreted finally through urine. The amount of xylose in urine is proportional to the activity of intestinal lactase. This represents a direct measure of hypo or normo lactasia.
Approval Year
PubMed
Patents
Sample Use Guides
In the randomized, dose-finding, phase I study, urine and serum pharmacokinetics of D-xylose were determined after oral administration of 6 ascending doses of gaxilose (and placebo) to 12 healthy adult volunteers. Gaxilose administration showed a progressive, dose-dependent increase in D-xylose in urine and serum. An optimal gaxilose dose of 0.45 g and urine collection periods of 4 and 5 hours were selected for further studies.
Route of Administration:
Oral
